DDInter923 DDInter1147
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin